Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
US-11896649-B2 · Feb 13, 2024 · US
Substituted carbonucleoside derivatives useful as anticancer agents
US10709709B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10709709-B2 |
| Application number | US-201816224016-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 18, 2018 |
| Priority date | Jun 6, 2016 |
| Publication date | Jul 14, 2020 |
| Grant date | Jul 14, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
First claim
Opening claim text (preview).
We claim: 1. A method of treating cancer in a mammal, the method comprising administering to the mammal in need thereof a therapeutically effective amount of the compound (1S,2S,3S,5R)-3((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, having the structure: or a pharmaceutically acceptable salt thereof wherein said cancer is selected from bladder cancer, breast cancer, cervical cancer, endometrial cancer, esophageal cancer, leukaemia, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, stomach cancer, cancer of the vulva, and head and neck cancer. 2. The method of claim 1 , wherein the cancer is lymphoma. 3. The method of claim 1 , wherein the cancer is esophageal cancer. 4. The method of claim 1 , wherein the cancer is stomach cancer. 5. The method of claim 1 , wherein the cancer is lung cancer. 6. The method of claim 1 , wherein the cancer is breast cancer. 7. The method of claim 1 , wherein the cancer is ovarian cancer. 8. The method of claim 1 , wherein the cancer is bladder cancer. 9. The method of claim 1 , wherein the cancer is cervical cancer. 10. The method of claim 1 , wherein the cancer is pancreatic cancer. 11. The method of claim 1 , wherein the cancer is leukemia. 12. The method of claim 1 , wherein the cancer is endometrial cancer. 13. The method of claim 1 , wherein the cancer is cancer of the vulva. 14. The method of claim 1 , wherein the cancer is head and neck cancer.
Assignees
Inventors
Classifications
Nitrogen atoms · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for metastasis · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10709709B2 cover?
- Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
- Who is the assignee on this patent?
- Pfizer
- What technology area does this patent fall under?
- Primary CPC classification A61K31/02. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).